PMID- 32652104
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 49
IP  - 3
DP  - 2020 Oct
TI  - Updates for the treatment of EGPA.
PG  - 104036
LID - S0755-4982(20)30024-5 [pii]
LID - 10.1016/j.lpm.2020.104036 [doi]
AB  - Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss 
      syndrome) is the least frequent antineutrophil cytoplasm antibody 
      (ANCA)-associated vasculitis (AAV). Major advances of our knowledge on its 
      pathophysiology have revealed features of both AAV and eosinophilic disorders. 
      The development of targeted biotherapies for both diseases opened new 
      possibilities for EGPA management. In this review, we highlight the rationale 
      underlying the routine treatment strategy, which relies mainly on 
      corticosteroids, with immunosuppressant adjunction for severe disease. However, 
      novel therapies are still needed for refractory/relapsing disease and to 
      alleviate the corticosteroid-dependence of asthma and chronic rhinosinusitis. At 
      present, the most promising biotherapies target either eosinophil biology, like 
      mepolizumab, an anti-interleukin-5, or the B-cell compartment, with rituximab. 
      Recent clinical data on new treatment options are discussed and therapeutic 
      strategies are proposed.
CI  - Copyright (c) 2020 Elsevier Masson SAS. All rights reserved.
FAU - Raffray, Loic
AU  - Raffray L
AD  - Department of Internal Medicine, Felix-Guyon University Hospital of La Reunion, 
      CS11021, Saint Denis, Reunion.
FAU - Guillevin, Loic
AU  - Guillevin L
AD  - Referral Center for Rare Systemic and Autoimmune Diseases, Department of Internal 
      Medicine, Hopital Cochin, Universite Paris Descartes, 27, rue du 
      Faubourg-Saint-Jacques, 75679 Paris Cedex 14, France. Electronic address: 
      loic.guillevin@aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200708
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 90Z2UF0E52 (mepolizumab)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Antibodies, Antineutrophil Cytoplasmic/adverse effects
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Biological Therapy/methods/trends
MH  - Churg-Strauss Syndrome/pathology/*therapy
MH  - Glucocorticoids/therapeutic use
MH  - Granulomatosis with Polyangiitis/pathology/therapy
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Rituximab/therapeutic use
EDAT- 2020/07/12 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/07/12 06:00
PHST- 2019/08/25 00:00 [received]
PHST- 2020/05/19 00:00 [revised]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/07/12 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2020/07/12 06:00 [entrez]
AID - S0755-4982(20)30024-5 [pii]
AID - 10.1016/j.lpm.2020.104036 [doi]
PST - ppublish
SO  - Presse Med. 2020 Oct;49(3):104036. doi: 10.1016/j.lpm.2020.104036. Epub 2020 Jul 
      8.